GLP-1 & incretins · compound

Semaglutide: GLP-1 Agonist Overview

In short

Semaglutide is a GLP-1 receptor agonist FDA-approved for weight management and type 2 diabetes. It is one of the most widely studied and prescribed incretin therapies. This page is educational only.

FDA-approved (Ozempic, Wegovy, Rybelsus)
Educational use · not medical advice

On this page

Semaglutide at a Glance

Type	GLP-1 receptor agonist
Targets	GLP-1 receptor
Half-life	~7 days
Administration	Subcutaneous injection (weekly) or oral
Primary research focus	Weight management and type 2 diabetes
Status	FDA-approved (Ozempic, Wegovy, Rybelsus)

What Is Semaglutide?

Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a hormone produced in the gut that plays a central role in glucose metabolism and appetite regulation. Developed by Novo Nordisk, it was engineered with structural modifications that extend its duration of action to approximately one week, making it suitable for once-weekly injection. It belongs to the broader class of GLP receptor agonists and is one of the most extensively studied compounds in the incretin therapy space.

Semaglutide is marketed under several brand names: Ozempic for type 2 diabetes management, Wegovy for chronic weight management in adults with obesity, and Rybelsus as the first oral GLP-1 receptor agonist approved for type 2 diabetes. Its dual-indication profile and robust clinical trial program have made it a cornerstone of modern metabolic medicine.

For a focused overview of semaglutide as a peptide compound, including amino acid structure and classification, see the semaglutide peptide profile.

How Semaglutide Works

GLP-1 Receptor Activation

Semaglutide mimics native GLP-1 by binding to and activating GLP-1 receptors expressed in the pancreas, brain, and gastrointestinal tract. In the pancreas, this promotes glucose-dependent insulin secretion and suppresses glucagon release, improving glycemic control. In the hypothalamus, GLP-1 receptor activation reduces appetite and food intake by modulating satiety signaling pathways. Semaglutide also slows gastric emptying, contributing to reduced caloric absorption and increased post-meal fullness.

Pharmacokinetics

The long half-life of approximately seven days is achieved through two key modifications: a fatty acid chain that enables strong non-covalent binding to serum albumin, and amino acid substitutions that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Albumin binding slows renal clearance and creates a circulating reservoir of the drug. These properties allow once-weekly subcutaneous dosing at steady state, with the oral formulation (Rybelsus) using an absorption enhancer (SNAC) to enable daily gastrointestinal uptake.

Research Findings

Semaglutide's efficacy has been established through the large-scale STEP (Semaglutide Treatment Effect in People with Obesity) and SUSTAIN trial programs, along with landmark cardiovascular outcome studies.

Study	Duration	Key Outcome
STEP 1	68 weeks	~15% mean weight loss vs placebo
STEP 2	68 weeks	Significant weight loss + HbA1c reduction in T2D
STEP 3	68 weeks	Enhanced weight loss with intensive lifestyle intervention
STEP 5	104 weeks	Sustained weight management over 2 years
SELECT	3+ years	20% reduction in major adverse cardiovascular events

Semaglutide Results Timeline

Individual responses vary based on dosage, adherence, diet, and baseline characteristics. The following timeline reflects commonly reported patterns from clinical trials and real-world use.

Timeframe	Commonly Reported Effects
Week 1–4	Appetite changes begin; mild nausea is common during initiation
Week 4–8	Dose escalation period; appetite reduction becomes more pronounced
Week 8–16	Noticeable weight loss as therapeutic doses are reached
Week 16–28	Significant weight reduction; most patients on maintenance dose
Week 28–52	Weight loss rate slows as body approaches new equilibrium
Week 52+	Long-term weight maintenance; continued metabolic benefits

For a detailed week-by-week breakdown, see the Semaglutide Results Timeline Guide.

Semaglutide vs Other GLP Peptides

Peptide	Receptors	Status	Key Difference
Semaglutide	GLP-1	FDA-approved	Single target, most real-world evidence
Tirzepatide	GLP-1 + GIP	FDA-approved	Dual target, greater weight loss in trials
Retatrutide	GLP-1 + GIP + Glucagon	Investigational	Triple target, highest trial weight loss

Tools and Calculators

Research Protocol Guides

Explore educational protocol references related to semaglutide and GLP-1 agonist research.

Semaglutide FAQs

What receptor does semaglutide activate?

Semaglutide selectively activates the GLP-1 (glucagon-like peptide-1) receptor. This mimics the natural incretin hormone that regulates appetite, insulin secretion, and gastric emptying. It does not act on GIP or glucagon receptors, unlike newer dual- or triple-agonist peptides.

How does semaglutide differ from tirzepatide?

Semaglutide targets only the GLP-1 receptor, while tirzepatide targets both GLP-1 and GIP receptors. Clinical trials show tirzepatide may produce greater average weight loss. However, semaglutide has more long-term real-world evidence and a larger body of published safety data.

How long do semaglutide results take?

Appetite changes commonly appear within the first four weeks. Noticeable weight loss is typically reported between weeks 8 and 16 as doses escalate. Maximum effects in clinical trials were generally observed around weeks 28 to 52, with maintenance continuing beyond one year.

Is semaglutide FDA-approved?

Yes. Semaglutide is FDA-approved under multiple brand names: Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral formulation for type 2 diabetes). Approved indications and availability may vary by country and regulatory body.

Can a calculator tell me what dose to take?

No. PeptideUniv calculators perform measurement math only — converting between mg, mL, and syringe units based on concentration. They do not provide dosing recommendations, medical advice, or treatment plans. Consult a licensed healthcare provider for dosing guidance.

What is the half-life of semaglutide?

Semaglutide has an elimination half-life of approximately seven days. This long duration is achieved through albumin binding and structural modifications that resist DPP-4 degradation, enabling once-weekly subcutaneous injection or daily oral administration.

For educational and research purposes only. Not medical advice. Consult a licensed clinician for personal guidance.